Prev Close | 237.05 |
Open | 235.16 |
Day Low/High | 231.76 / 237.64 |
52 Wk Low/High | 207.35 / 261.52 |
Volume | 1.42M |
Prev Close | 237.05 |
Open | 235.16 |
Day Low/High | 231.76 / 237.64 |
52 Wk Low/High | 207.35 / 261.52 |
Volume | 1.42M |
Exchange | NYSE |
Shares Outstanding | 187.99B |
Market Cap | 47.18B |
P/E Ratio | 21.86 |
Div & Yield | N.A. (N.A) |
Eight of these 11 trade ideas are in the green, with a few big winners.
While consolidation may be key to the cannabis market in 2019, this IPO is worthy of a deeper dive.
CBD could make coffee an around the clock craze.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
I'm strategizing a risk reversal here using a put sale to fund a long-side play.
Even formerly bearish analysts are changing their tune as the risks appear to be fully baked in at this point.
A number of analysts maintain the beer and wine giant's valuation is even more attractive for long-term investors thanks to a sharp decline in its shares.
Even with its 12% stock decline on Wednesday, Constellation Brands is more intriguing than it was yesterday.
The company's third quarter was a mixed bag.
It's amazing how this business works. I launched my Canopy Growth Corp. analysis about three weeks ago in conjunction with my analysis of Constellation Brands (down by -$21/share today) -- as STZ had recently made the big investment in CGC. My concl...
Plus, a resolution of the government shut-down needs to happen soon.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
Aggressive traders could probe the long side of STZ at current levels and on a shallow dip.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Perhaps no company has bought into the Canadian cannabis craze more than Constellation Brands.
Pot stock partnerships are a gateway to gains for cannabis investors.
The stock is finally down to realistic levels.
After Altria's investment in Cronos Group, which cannabis company will be the next target?
Turns to the upside and downside can be subtle but it looks like Constellation Brands is giving us some subtle bullish clues.
Here are 4 stocks that can be bought into the stock cyclone that might occur if things don't go the bulls way in the Argentine.
Perhaps the highest profile impact on Tilray equity performance has been the interest of Andrew Left of Citron Research.
Tilray will have a lot to tackle this evening.
Consumer Discretionary stocks were the hottest on Wednesday, though all eleven sectors easily finished in the green.
Cannabis and tobacco are hard to equate, which Barclays' primer on the Cannabis industry misses.